Detlef Scholz is president of credit ratings at Morningstar responsible for all aspects of the company’s global credit ratings business, which is headquartered in Toronto, Canada. Prior to this role, Detlef served as managing director and head of Europe at DBRS, a global credit ratings agency acquired by Morningstar in 2019. Detlef has more than 25 years of experience in the credit ratings industry. Prior to joining DBRS, Detlef worked for Moody’s Investors Service in Frankfurt, New York and London. Detlef held a range of positions, including, Managing Director – Ratings Management, Global Head of Structured Finance and Global Head of Financial Institutions while at Moody’s. Detlef holds a degree in Business Administration from the University of St. Gallen in Switzerland.
Oliver Gabbay has over 16 years of business, finance and fintech experience. Oliver previously worked as the Chief Operating Officer of Aztec Exchange, a Forbes Fintech 50 company in the trade finance arena. Prior to that he worked at a hedge fund in Singapore sponsored by Brummer & Partners. He began his finance career working with HSBC as a portfolio manager on a multi billion dollar structured credit portfolio and was a part of a number one rated securitisation research team at Dresdner Kleinwort Wasserstein. He holds a BSc in Economics from UCL as well as an MSc (Distinction) in Finance.
Angus Duncan is a partner at Hunton Andrews Kurth LLP. Ranked by Chambers Global, Chambers UK and The Legal 500, Angus is known for his thorough grasp of laws surrounding European finance transactions, particularly those involving the securitisation of assets. Recently, his practice has focused on new entrants to the financial markets, both in the UK and overseas. He also assists clients with insurance-linked securities, including catastrophe bonds, sidecars, industry loss warranties and privately placed transactions with respect to catastrophe, mortality and longevity risk using the capital markets. A pioneering structured finance lawyer, he has worked on a number of market firsts including the first catastrophe bond transaction incorporating a tri-partite repo structure (Eurus II).
Chris is a renowned British Professor of Clinical Oncology and medical consultant. He has served as Chairman of the National Cancer Research Institute Committee (NCRI) for head and neck cancer research, and as the National Clinical Lead in Head and Neck Cancer by the Department of Health (UK) and the Cancer Services Collaborative. In 2007 he became President of the British Oncological Association. Chris has both a private and an NHS practice at The Royal Marsden and has private practice at the Harley Street Clinic. He is a Member of the Royal College of Physicians (UK) and Fellow of the Royal College of Radiologists (UK) and holds Certification of European Society of Medical Oncology. He holds the highest UK medical awards including FMedSci, MFIPEM and FInstPhys. Chris qualified from UCL, University of London and was awarded MD in 2001 and PhD in 2012. Chris also undertook a period of study at Imperial College Business School and was awarded the Advanced Certificate in Health Care Management (University of London) in 2000. Chris is on the board of various charities and medical R&D companies.